Home> Products> post meal blood sugar spikes

{ "products": [ { "_id": "67c587d0e675be0e779bdf25", "fptag": "STERISHEALTHCAREPVTLTDADA8", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "RAPIGLINIDE 0.5", "description": "RAPIGLINIDE 0.5 contains Repaglinide 0.5 mg, a medication used in the treatment of Type 2 diabetes mellitus. It belongs to a class of drugs known as meglitinides, which help control blood sugar levels by stimulating insulin production from the pancreas. RAPIGLINIDE is commonly prescribed to individuals who are unable to maintain optimal blood glucose levels through diet and exercise alone. It can be used alone or in combination with other oral diabetes medications to help manage blood sugar levels effectively.\n\n \nKey Benefits:\n \n Effective Blood Sugar Control – Helps lower postprandial blood glucose levels, effectively managing blood sugar spikes after meals.\n Rapid Action – Starts working quickly, offering fast relief from elevated blood sugar levels.\n Flexible Dosing – Can be taken before meals, giving flexibility in meal planning and diabetes management.\n Helps Prevent Complications of Diabetes – By controlling blood sugar levels, it helps in reducing the risk of complications associated with diabetes, such as nerve damage, heart disease, and kidney issues.\n Used Alone or with Other Diabetes Medications – RAPIGLINIDE 0.5 can be combined with other oral diabetes drugs for better blood sugar management.\n\n \nHow Does It Work?\n \n\nRepaglinide 0.5 mg works by stimulating the beta cells in the pancreas to secrete insulin when blood sugar levels rise after meals. The medication acts quickly, allowing the body to use glucose more effectively and preventing high blood sugar spikes. Unlike other long-acting insulin medications, Repaglinide acts quickly but for a short duration, making it suitable for controlling blood sugar right after eating. It helps in maintaining optimal postprandial glucose levels, which is crucial for the management of Type 2 diabetes.\n\n \nDirections for Use:\n \n\nTake RAPIGLINIDE 0.5 exactly as prescribed by your doctor.\nThe typical dosage is 0.5 mg to 2 mg taken before meals, 2 to 3 times daily.\nSwallow the tablet whole with water.\nDo not take more than the prescribed dose, and never skip doses.\nIf you miss a dose, take it as soon as you remember before the next meal. If it's almost time for your next meal, skip the missed dose—do not double the dose.\n \nSide Effects:\n \n\nWhile RAPIGLINIDE 0.5 is generally well-tolerated, some people may experience:\n\nHypoglycemia (low blood sugar): Symptoms include dizziness, sweating, shaking, confusion, and headaches.\nNausea or diarrhea\nWeight gain (in some cases)\nHeadache or dizziness\nRash or itching (rare)\nAbdominal discomfort\nIf you experience any signs of severe hypoglycemia (such as confusion, blurred vision, or seizures), or severe allergic reactions (such as difficulty breathing, swelling of the face or throat), seek immediate medical attention.", "price": 217.0, "discountamount": 66.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 0, "_keywords": [ "2 mg", "05 mg", "rapiglinide 05", "meals 2", "pancreas rapiglinide", "repaglinide 05 mg", "rapiglinide 05rapiglinide 05", "meal skip", "prescribed dose", "meal planning", "commonly prescribed", "medical attention", "throat seek", "dizziness rash", "cases headache", "headaches nausea", "generally welltolerated", "missed dosedo", "skip doses", "typical dosage", "beta cells", "kidney issues", "severe hypoglycemia", "secrete insulin", "oral diabetes drugs", "stimulating insulin production", "meals giving flexibility", "dose side effects", "blood sugar management", "oral diabetes medications", "severe allergic reactions", "difficulty breathing swelling", "confusion blurred vision", "diarrhea weight gain", "controlling blood sugar", "short duration making" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1387, "imageuri": "https://bizimages.withfloats.com/actual/440185d0683c4e03b69f9ca135796362.jpg", "tileimageuri": "https://bizimages.withfloats.com/actual/440185d0683c4e03b69f9ca135796362.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-03-03T10:43:28.078Z", "updatedon": "2025-03-03T10:44:10.702Z", "buyonlinelink": null, "producturl": "https://www.sterispharma.com/medicines/rapiglinide-0-5/1387", "availableunits": -1.0, "iscodavailable": true, "isprepaidonlineavailable": true, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Repaglinide 0.5mg", "category": "Diabetic Range", "tags": [ "Repaglinide 0.5 mg tablet uses", "Repaglinide 1 mg uses", "Repaglinide 0.5 mg brand name", "Repaglinide brand name", "Repaglinide 0.5 Mg Tablet Uses in Hindi" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "AssuredPurchase", "producttype": "products", "hsncode": "", "gstslab": 12.0, "isnotforsale": false }, { "_id": "674b0bf7c8795ffe2c8d69dd", "fptag": "STERISHEALTHCAREPVTLTDADA8", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLIMITERIS TRIO 0.5/0.2/500 ", "description": "Diabetes management often requires a multifaceted approach to address the complexities of glucose regulation. Glimiteris Trio 0.5/0.2/500 offers a synergistic combination of three proven antidiabetic agents. This tablet not only targets fasting and postprandial blood glucose but also improves the body’s insulin utilization, ensuring better glycemic control and reducing the risk of complications associated with diabetes.\n\n \nKey Benefits:\nEffective Blood Sugar Management: Works on multiple pathways to control both fasting and postprandial blood glucose levels.\n\nReduces Insulin Resistance: Enhances the body's response to insulin, improving its efficacy.\nMinimizes Post-Meal Glucose Spikes: Voglibose slows carbohydrate digestion and absorption, keeping postprandial glucose in check.\nImproves Long-Term Glycemic Control: Helps in achieving and maintaining stable HbA1c levels.\nSustained Release Formula: Metformin’s SR formulation ensures prolonged action, reducing the need for frequent dosing.\nComprehensive Diabetes Management: Prevents complications like neuropathy, retinopathy, and cardiovascular issues associated with diabetes.\nHow Does It Work?\nGlimepiride: Stimulates the pancreas to release insulin, directly lowering blood glucose levels.\n\nVoglibose: Inhibits enzymes that break down carbohydrates into glucose, thereby delaying glucose absorption and controlling post-meal spikes.\nMetformin Hydrochloride SR: Decreases hepatic glucose production, enhances peripheral glucose uptake, and improves insulin sensitivity, ensuring balanced glucose levels throughout the day.\nTogether, these three ingredients address the multifaceted nature of type 2 diabetes, providing a holistic solution for effective blood sugar control.\n\nDirections for Use:\nDosage: Take one tablet as prescribed by your healthcare professional, usually once or twice daily with meals.\nSwallow Whole: Do not crush or chew the tablet; it is designed for sustained release.\nTiming: Preferably consume with a meal to reduce gastrointestinal discomfort and optimize efficacy.\nFollow Medical Advice: Stick to the prescribed dosage and schedule for optimal results.\nAlways consult your doctor before starting or adjusting your dosage.\n\nSide Effects:\nWhile Glimiteris Trio 0.5/0.2/500 is generally well-tolerated, some individuals may experience side effects, including:\n\nCommon Side Effects:\n\nNausea, vomiting, or diarrhea\nStomach discomfort or flatulence\nMild hypoglycemia (low blood sugar levels)\nRare but Serious Side Effects:\n\nSevere hypoglycemia\nLactic acidosis (from Metformin)\nAllergic reactions such as rash or itching", "price": 153.0, "discountamount": 46.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 0, "_keywords": [ "prescribed dosage", "ingredients address", "glycemic control", "targets fasting", "generally welltolerated", "glimiteris trio 0502500", "optimal results", "meals swallow", "healthcare professional", "holistic solution", "multifaceted nature", "cardiovascular issues", "neuropathy retinopathy", "insulin improving", "bodys response", "multiple pathways", "synergistic combination", "multifaceted approach", "dosage side effects", "delaying glucose absorption", "postprandial blood glucose", "metformin allergic reactions", "diarrhea stomach discomfort", "experience side effects", "reduce gastrointestinal discomfort", "work glimepiride stimulates", "proven antidiabetic agents" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1326, "imageuri": "https://bizimages.withfloats.com/actual/a0afb3b2ebc94f2784eb63f03d93998d.jpg", "tileimageuri": "https://bizimages.withfloats.com/actual/a0afb3b2ebc94f2784eb63f03d93998d.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-11-30T12:58:31.022Z", "updatedon": "2024-11-30T12:59:37.716Z", "buyonlinelink": null, "producturl": "https://www.sterispharma.com/medicines/glimiteris-trio-0-5-0-2-500-/1326", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": true, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Glimepiride 0.5 mg, Voglibose 0.2 mg & Metformin Hydrochloride (SR) 500 mg Tablets", "category": "Diabetic Range", "tags": [ "Glimepiride 0.5 mg,", "Voglibose 0.2 mg", "Hydrochloride (SR) 500 mg Tablets", "uses of Hydrochloride (SR) 500 mg Tablets", "benefits of Voglibose 0.2 Mg" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "AssuredPurchase", "producttype": "products", "hsncode": "", "gstslab": 12.0, "isnotforsale": false }, { "_id": "670cf4b5bc76fdbfa23f2242", "fptag": "STERISHEALTHCAREPVTLTDADA8", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLICLAGLAZE TRIO 40/0.3 ", "description": "GLICLAGLAZE TRIO 40/0.3 is a prescription medication used for managing type 2 diabetes. It contains a combination of three active ingredients—Gliclazide IP (40 mg), Metformin Hydrochloride IP (500 mg), and Voglibose IP (0.3 mg)—each targeting different pathways to help control blood sugar levels.\n\n \nKey Benefits:\n \n\nProvides comprehensive blood sugar control for patients with type 2 diabetes.\nReduces fasting and post-meal glucose levels.\nLowers the risk of complications associated with high blood sugar, such as cardiovascular issues and neuropathy.\n \nHow Does It Work?\n \n\nGliclazide enhances insulin secretion from the pancreas.\nMetformin decreases glucose production in the liver and improves insulin sensitivity.\nVoglibose slows the breakdown of carbohydrates in the intestines, minimizing sudden spikes in blood sugar levels after meals.\n \nDirections for Use:\n \n\nTake this medication as directed by your healthcare provider, typically once or twice daily with meals.\nSwallow the tablet whole with water.\nDo not crush or chew the tablet.\nRegularly monitor your blood sugar levels as advised by your doctor.\n \nSide Effects:\n \n\nCommon: Nausea, diarrhea, stomach pain, and low blood sugar (hypoglycemia).\nLess Common: Headaches, dizziness, and mild gastrointestinal discomfort.\nRare but Severe: Severe hypoglycemia, lactic acidosis (with metformin), or allergic reactions.", "price": 205.0, "discountamount": 62.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 0, "_keywords": [ "40 mg", "Voglibose IP", "stomach pain", "Side Effects", "Key Benefits", "Gliclazide IP", "sudden spikes", "lactic acidosis", "type 2 diabetes", "low blood sugar", "GLICLAGLAZE TRIO", "high blood sugar", "insulin secretion", "allergic reactions", "different pathways", "glucose production", "blood sugar levels", "Severe hypoglycemia", "healthcare provider", "insulin sensitivity", "cardiovascular issues", "prescription medication", "post-meal glucose levels", "three active ingredients", "Metformin Hydrochloride IP", "mild gastrointestinal discomfort", "comprehensive blood sugar control" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1118, "imageuri": "https://bizimages.withfloats.com/actual/f86c979758e146cfa7bd8d16a9e9810f.jpg", "tileimageuri": "https://bizimages.withfloats.com/actual/f86c979758e146cfa7bd8d16a9e9810f.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-10-14T10:38:45.286Z", "updatedon": "2024-10-30T09:23:41.908Z", "buyonlinelink": null, "producturl": "https://www.sterispharma.com/medicines/gliclaglaze-trio-40-0-3-/1118", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": true, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Gliclazide IP (40 mg), Metformin Hydrochloride IP (500 mg), Voglibose IP (0.3 mg)", "category": "Diabetic Range", "tags": [ "gliclazide+metformin+voglibose combination brand names", "Voglibose Metformin Glimepiride combination", "Gliclazide and Metformin hydrochloride and Voglibose tablets" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "AssuredPurchase", "producttype": "products", "hsncode": "", "gstslab": 12.0, "isnotforsale": false }, { "_id": "66ebca0d7c059506c0ced3bb", "fptag": "STERISHEALTHCAREPVTLTDADA8", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VOGLISLOW G3 M 0.3 ", "description": "VOGLISLOW G3 M 0.3 is a combination medication used to manage type 2 diabetes mellitus. It combines three active ingredients: Voglibose (0.3 mg), Glimepiride (3 mg), and Metformin Hydrochloride (500 mg). This combination helps regulate blood sugar levels, providing an effective treatment option for individuals who require multi-action control of their diabetes.\n\n \n\nKey Ingredients:\n \nVoglibose (0.3 mg): A type of alpha-glucosidase inhibitor that slows down carbohydrate absorption in the intestines, reducing post-meal blood glucose spikes.\nGlimepiride (3 mg): A sulfonylurea, which stimulates the pancreas to release more insulin, helping lower blood sugar levels.\nMetformin Hydrochloride (500 mg): A biguanide that works by reducing the amount of glucose produced by the liver and improving insulin sensitivity, making the body more effective at utilizing glucose.\n \n\nKey Benefits:\n \n\nEffective Blood Sugar Control: By combining three active agents, VOGLISLOW G3 M 0.3 provides comprehensive control of blood sugar levels in individuals with type 2 diabetes.\nReduces Post-Meal Blood Sugar Spikes: Voglibose slows down the absorption of carbohydrates, helping to reduce sudden increases in blood glucose after meals.\nEnhances Insulin Sensitivity: Metformin improves the body’s response to insulin, promoting better glucose absorption and utilization.\nStimulates Insulin Production: Glimepiride encourages the pancreas to release more insulin, further helping to reduce blood sugar levels.\n \n\nHow Does It Work?\n\nVOGLISLOW G3 M 0.3 works through a multi-faceted approach:\n\nVoglibose delays the breakdown and absorption of carbohydrates in the intestines, leading to slower and more controlled rises in blood sugar after eating.\nGlimepiride stimulates insulin production from the pancreas, which helps in controlling blood sugar levels.\nMetformin works by decreasing glucose production in the liver and enhancing insulin sensitivity, making it easier for cells to absorb and use glucose.\nTogether, these three actions ensure better glycemic control in patients with type 2 diabetes.\n\n \n\nDirections for Use:\n \n\nVOGLISLOW G3 M 0.3 should be taken as directed by your healthcare provider.\nUsually, the medication is taken with meals to reduce gastrointestinal side effects and to enhance the efficacy of Voglibose in controlling post-meal glucose spikes.\nDo not crush or chew the tablet; swallow it whole with water.\nEnsure that the dosage and timing are strictly followed as per the doctor\\\\\\\\'s advice.\n \n\nSide Effects:\n\nCommon side effects of VOGLISLOW G3 M 0.3 include:\n\nGastrointestinal issues: Bloating, diarrhea, or abdominal discomfort, particularly due to Metformin.\nHypoglycemia: Low blood sugar, especially in combination with other antidiabetic drugs or if meals are skipped.\nDizziness or headache: These may occur as the body adjusts to the medication.\nSkin reactions: In rare cases, rashes or allergic reactions may develop.", "price": 185.0, "discountamount": 56.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 0, "_keywords": [ "3 mg", "500 mg", "rare cases", "Key Benefits", "three actions", "Skin reactions", "VOGLISLOW G3 M", "Key Ingredients", "Low blood sugar", "controlled rises", "sudden increases", "glycemic control", "glucose absorption", "Insulin Production", "allergic reactions", "glucose production", "blood sugar levels", "insulin sensitivity", "healthcare provider", "Common side effects", "three active agents", "abdominal discomfort", "multi-action control", "comprehensive control", "combination medication", "multi-faceted approach", "Metformin Hydrochloride", "carbohydrate absorption", "Gastrointestinal issues", "type 2 diabetes mellitus", "three active ingredients", "other antidiabetic drugs", "post-meal glucose spikes", "effective treatment option", "alpha-glucosidase inhibitor", "Post-Meal Blood Sugar Spikes", "gastrointestinal side effects", "Effective Blood Sugar Control", "post-meal blood glucose spikes" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1099, "imageuri": "https://bizimages.withfloats.com/actual/fcca6b41201448088cd9a1f20709ca9f.jpg", "tileimageuri": "https://bizimages.withfloats.com/actual/fcca6b41201448088cd9a1f20709ca9f.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-09-19T06:51:57.447Z", "updatedon": "2024-10-30T10:01:08.718Z", "buyonlinelink": null, "producturl": "https://www.sterispharma.com/medicines/voglislow-g3-m-0-3-/1099", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": true, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Voglibose 0.3 mg , Glimepride 3 mg , Metformin Hydrochloride 500 mg", "category": "Diabetic Range", "tags": [ "voglibose glimepiride + metformin hydrochloride uses in hindi", "voglibose glimepiride + metformin hydrochloride uses", "Glimepiride 3mg Metformin 500mg Voglibose 0.3 mg brand name" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "AssuredPurchase", "producttype": "products", "hsncode": "", "gstslab": 0.0, "isnotforsale": false }, { "_id": "66d834f3ed345980e0fca519", "fptag": "STERISHEALTHCAREPVTLTDADA8", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLICLAGLAZE TRIO 0.3 ", "description": "GLICLAGLAZE TRIO 0.3 \nVoglibose (0.3mg), Metformin (500mg), Gliclazide (80mg)\nGLICLAGLAZE TRIO 0.3 is a powerful combination medication designed to manage and control type 2 diabetes. It is formulated with three active ingredients: Voglibose, Metformin, and Gliclazide. This unique combination helps to regulate blood sugar levels effectively, providing a comprehensive approach to diabetes management. GLICLAGLAZE TRIO 0.3 is particularly useful for patients who require a multifaceted treatment strategy to keep their blood glucose levels in check.\n\n \n\nKey Benefits:\n \n\nEffective Blood Sugar Control: The combination of Voglibose, Metformin, and Gliclazide offers a synergistic effect, providing comprehensive control over blood sugar levels.\nPrevents Post-Meal Sugar Spikes: Voglibose helps in delaying glucose absorption, reducing the risk of hyperglycemia after meals.\nImproved Insulin Sensitivity: Metformin enhances the body's response to insulin, ensuring better glucose management.\nEnhanced Insulin Secretion: Gliclazide helps in stimulating insulin release from the pancreas, making it easier to maintain stable blood sugar levels.\n \n\nHow Does It Work?\n \n\nGLICLAGLAZE TRIO 0.3 works through a multi-pronged approach to manage diabetes. Voglibose slows down the absorption of carbohydrates in the gut, which helps to prevent rapid increases in blood sugar levels after meals. Metformin reduces the liver's glucose production and improves insulin sensitivity, ensuring better glucose uptake and utilization. Gliclazide stimulates the pancreas to release insulin, aiding in the reduction of blood glucose levels.\n\n \n\nDirections for Use:\n \n\nTake GLICLAGLAZE TRIO 0.3 as prescribed by your healthcare provider. It is typically taken before meals to maximize its effectiveness in controlling postprandial blood sugar spikes. Swallow the tablet whole with a glass of water. Do not crush or chew the tablet. Your doctor will determine the appropriate dosage and frequency based on your individual health needs.\n\n \n\nSide Effects:\n \n\nLike all medications, GLICLAGLAZE TRIO 0.3 may cause some side effects. Common side effects include gastrointestinal disturbances such as nausea, diarrhea, and abdominal pain. Hypoglycemia (low blood sugar) may occur, especially if you skip meals or engage in intense physical activity. Other possible side effects include dizziness, headache, and fatigue. If you experience any severe side effects or allergic reactions, seek medical attention immediately.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n", "price": 185.0, "discountamount": 56.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 0, "_keywords": [ "Key Benefits", "abdominal pain", "glucose uptake", "type 2 diabetes", "rapid increases", "insulin release", "low blood sugar", "GLICLAGLAZE TRIO", "medical attention", "glucose absorption", "allergic reactions", "appropriate dosage", "synergistic effect", "unique combination", "glucose production", "glucose management", "diabetes management", "healthcare provider", "severe side effects", "Common side effects", "blood glucose levels", "comprehensive control", "multi-pronged approach", "comprehensive approach", "Post-Meal Sugar Spikes", "individual health needs", "three active ingredients", "intense physical activity", "stable blood sugar levels", "Enhanced Insulin Secretion", "Other possible side effects", "Improved Insulin Sensitivity", "gastrointestinal disturbances", "Effective Blood Sugar Control", "powerful combination medication", "multifaceted treatment strategy", "postprandial blood sugar spikes" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1079, "imageuri": "https://bizimages.withfloats.com/actual/2f134a4e5bfd4ff79eabca9bf99852ab.jpg", "tileimageuri": "https://bizimages.withfloats.com/actual/2f134a4e5bfd4ff79eabca9bf99852ab.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-09-04T10:22:43.327Z", "updatedon": "2024-09-04T10:36:15Z", "buyonlinelink": null, "producturl": "https://www.sterispharma.com/medicines/gliclaglaze-trio-0-3-/1079", "availableunits": -1.0, "iscodavailable": true, "isprepaidonlineavailable": true, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Voglibose (0.3mg), Metformin (500mg), Gliclazide (80mg)", "category": "Diabetic Range", "tags": [ "Voglibose (0.3mg), Metformin (500mg), Gliclazide (80mg) uses", "Voglibose (0.3mg), Metformin (500mg), Gliclazide (80mg) uses in hindi", "voglibose (0.3mg) metformin (500mg) gliclazide (80mg) side effects" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "AssuredPurchase", "producttype": "products", "hsncode": "", "gstslab": 12.0, "isnotforsale": false }, { "_id": "662cf153e68e121fa88613de", "fptag": "STERISHEALTHCAREPVTLTDADA8", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VOGLIGOLD 0.3 ", "description": "VOGLIGOLD 0.3 \nVoglibose (0.3mg)\nIntroduction\nEffective management of Type 2 diabetes involves maintaining stable blood glucose levels, especially after meals. VOGLIGOLD 0.3, containing 0.3mg of Voglibose, provides a strategic approach to controlling postprandial hyperglycemia, which is a common challenge for those managing diabetes. This article explores the use of Voglibose, its mechanism of action, and the benefits it brings to diabetes care.\n\nWhat is Voglibose?\nVoglibose is an alpha-glucosidase inhibitor, a type of medication that helps manage blood sugar levels by affecting the absorption of carbohydrates in the digestive system. It is particularly effective in reducing blood sugar spikes that occur after eating, making it an essential tool for individuals with Type 2 diabetes who struggle with these fluctuations.\n\nMechanism of Action\nVoglibose works by inhibiting alpha-glucosidase enzymes in the small intestine. These enzymes play a crucial role in the digestion of complex carbohydrates, breaking them down into simpler sugars that are absorbed into the bloodstream. By blocking these enzymes, Voglibose slows the breakdown and absorption of carbohydrates, leading to a more gradual increase in blood glucose levels after meals.\n\nBenefits of VOGLIGOLD 0.3\nControlled Postprandial Blood Sugar\nThe primary benefit of VOGLIGOLD 0.3 is its ability to moderate the rise in blood glucose levels following meals. This controlled release helps prevent the sharp spikes that can contribute to the long-term complications associated with diabetes, such as cardiovascular disease and nerve damage.\n\nLower Risk of Hypoglycemia\nUnlike some diabetes medications that stimulate insulin production, Voglibose does not directly affect insulin levels. As a result, it is associated with a lower risk of hypoglycemia, a condition where blood sugar levels fall too low, which can be particularly dangerous for individuals with diabetes.\n\nWeight Neutral\nVoglibose does not contribute to weight gain, which is an important consideration for many individuals with Type 2 diabetes. Managing body weight is often a key part of controlling diabetes, and using a weight-neutral medication like Voglibose can help in achieving overall health goals.\n\nIdeal Candidates for VOGLIGOLD 0.3\nVOGLIGOLD 0.3 is ideal for individuals with Type 2 diabetes who:\n\nExperience significant increases in blood sugar levels after meals.\nNeed a supplement to their existing diabetes medication regimen to better control postprandial hyperglycemia.\nAre looking for a treatment option with minimal risk of hypoglycemia and no impact on weight.\nDosage and Administration\nThe typical dosage of VOGLIGOLD 0.3 is one tablet of 0.3mg taken three times a day, administered at the start of each meal. This timing ensures that Voglibose is active in the digestive system when it can be most effective in slowing carbohydrate absorption.\n\nPotential Side Effects\nWhile VOGLIGOLD 0.3 is generally safe and well-tolerated, some individuals may experience mild gastrointestinal side effects, including:\n\nGas\nBloating\nDiarrhea\nThese side effects are usually temporary and often resolve as the body adjusts to the medication.\n For further information: \n EMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP:: 7877551268, 8209542042, 8955945010, 6377716668\nhttps://www.sterisonline.com/product/vogligold-0-3-133457", "price": 119.0, "discountamount": 35.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 0, "_keywords": [ "use", "tool", "rise", "EMAIL", "0.3mg", "meals", "start", "result", "timing", "impact", "action", "ability", "article", "benefits", "key part", "Bloating", "Diarrhea", "breakdown", "digestion", "Voglibose", "VOGLIGOLD", "condition", "mechanism", "one tablet", "supplement", "Lower Risk", "bloodstream", "body weight", "information", "weight gain", "Hypoglycemia", "Introduction", "sterispharma", "fluctuations", "sterisonline", "sharp spikes", "crucial role", "minimal risk", "nerve damage", "diabetes care", "CALL/WHATSAPP", "Administration", "insulin levels", "simpler sugars", "Weight Neutral", "typical dosage", "small intestine", "Type 2 diabetes", "primary benefit", "common challenge", "digestive system", "gradual increase", "treatment option", "Ideal Candidates", "many individuals", "insulin production", "blood sugar levels", "blood sugar spikes", "strategic approach", "controlled release", "Effective management", "overall health goals", "diabetes medications", "complex carbohydrates", "significant increases", "Potential Side Effects", "cardiovascular disease", "long-term complications", "carbohydrate absorption", "important consideration", "weight-neutral medication", "alpha-glucosidase enzymes", "postprandial hyperglycemia", "stable blood glucose levels", "alpha-glucosidase inhibitor", "mild gastrointestinal side effects", "Controlled Postprandial Blood Sugar", "existing diabetes medication regimen" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 950, "imageuri": "https://bizimages.withfloats.com/actual/f7b58b66ebc94f1094de98bdcf86aa19.jpg", "tileimageuri": "https://bizimages.withfloats.com/actual/f7b58b66ebc94f1094de98bdcf86aa19.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-04-27T12:36:35.066Z", "updatedon": "2024-06-22T12:59:20Z", "buyonlinelink": null, "producturl": "https://www.sterispharma.com/medicines/vogligold-0-3-/950", "availableunits": -1.0, "iscodavailable": true, "isprepaidonlineavailable": true, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Voglibose (0.3mg)", "category": "Diabetic Range", "tags": [ "vogli 0.3 price", "vogli 0.3mg tab", "vogli 0.3 dosage", "vogli 0.3 composition", "vogli 0.3 tablet uses" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "AssuredPurchase", "producttype": "products", "hsncode": "", "gstslab": 12.0, "isnotforsale": false }, { "_id": "662cea4f9166a51f7ccc3eb7", "fptag": "STERISHEALTHCAREPVTLTDADA8", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VOGLIGOLD 0.2 ", "description": "VOGLIGOLD 0.2 \nVoglibose (0.2mg)\nIntroduction\nManaging postprandial blood glucose is a crucial aspect of controlling Type 2 diabetes and minimizing the risk of complications. VOGLIGOLD 0.2, containing 0.2mg of Voglibose, offers a targeted approach to managing glucose levels after meals. This article explores how Voglibose works, its benefits, and its role in the overall treatment regimen for diabetes patients.\n\nWhat is Voglibose?\nVoglibose is an alpha-glucosidase inhibitor, a class of oral antidiabetic drugs that play a crucial role in managing postprandial hyperglycemia (high blood sugar after eating). Unlike other diabetes medications that increase insulin secretion or enhance insulin sensitivity, Voglibose works by delaying the absorption of carbohydrates in the intestines. This action results in a more gradual rise in blood glucose levels following meals, making it an effective option for controlling spikes in blood sugar that are typical after eating.\n\nMechanism of Action\nVoglibose inhibits enzymes called alpha-glucosidases located in the intestinal brush border. These enzymes are responsible for breaking down complex carbohydrates into glucose. By inhibiting these enzymes, Voglibose slows down carbohydrate digestion and the consequent absorption of glucose. This leads to a significant reduction in the rate and extent of blood sugar rise after meals.\n\nBenefits of VOGLIGOLD 0.2\nImproved Postprandial Glucose Control\nVOGLIGOLD 0.2 is particularly effective in controlling blood sugar spikes after meals, a common challenge for many people with Type 2 diabetes. Regular use of Voglibose can help smooth out the daily peaks of blood glucose levels, which are linked to an increased risk of developing long-term diabetes complications.\n\nReduced Risk of Hypoglycemia\nBecause Voglibose acts by slowing glucose absorption and does not stimulate insulin secretion directly, it is associated with a lower risk of causing hypoglycemia compared to some other diabetes medications that increase insulin output from the pancreas.\n\nWeight Neutral\nVoglibose is considered weight neutral, meaning it does not contribute to weight gain. This is an important advantage since many individuals with Type 2 diabetes are also managing their weight as part of their overall health strategy.\n For further information: \n EMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP:: 7877551268, 8209542042, 8955945010, 6377716668 \nhttps://www.sterisonline.com/product/vogligold-0-2-133456", "price": 89.0, "discountamount": 26.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 0, "_keywords": [ "part", "0.2mg", "EMAIL", "meals", "class", "action", "option", "extent", "article", "enzymes", "pancreas", "benefits", "Mechanism", "Voglibose", "VOGLIGOLD", "intestines", "lower risk", "daily peaks", "weight gain", "information", "Regular use", "many people", "Reduced Risk", "crucial role", "sterisonline", "gradual rise", "Hypoglycemia", "sterispharma", "Introduction", "CALL/WHATSAPP", "crucial aspect", "insulin output", "increased risk", "Weight Neutral", "Type 2 diabetes", "many individuals", "common challenge", "high blood sugar", "targeted approach", "diabetes patients", "insulin secretion", "blood sugar spikes", "glucose absorption", "important advantage", "insulin sensitivity", "blood glucose levels", "significant reduction", "consequent absorption", "complex carbohydrates", "carbohydrate digestion", "oral antidiabetic drugs", "intestinal brush border", "overall health strategy", "overall treatment regimen", "postprandial hyperglycemia", "postprandial blood glucose", "other diabetes medications", "alpha-glucosidase inhibitor", "long-term diabetes complications", "Improved Postprandial Glucose Control" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 949, "imageuri": "https://bizimages.withfloats.com/actual/a7f3b4aa989a457894687d4ccf65500c.jpg", "tileimageuri": "https://bizimages.withfloats.com/actual/a7f3b4aa989a457894687d4ccf65500c.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-04-27T12:06:39.932Z", "updatedon": "2024-04-27T12:06:39.932Z", "buyonlinelink": null, "producturl": "https://www.sterispharma.com/medicines/vogligold-0-2-/949", "availableunits": -1.0, "iscodavailable": true, "isprepaidonlineavailable": true, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Voglibose (0.2mg)", "category": "Diabetic Range", "tags": [ "Volibo", "Volix", "PPG", "Vobose", "Voglitor", "Vogli", "Voglistar", "Vozuca", "Voglinorm", "Voglimac" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "AssuredPurchase", "producttype": "products", "hsncode": "", "gstslab": 0.0, "isnotforsale": false }, { "_id": "662cd9d93d1e541c58029df3", "fptag": "STERISHEALTHCAREPVTLTDADA8", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VILDIABATE PIO ", "description": "VILDIABATE PIO \nVildagliptin 50 mg & Pioglitazone Hydrochloride 15 mg\nIntroduction\nType 2 diabetes management often necessitates a multidimensional treatment strategy to effectively control blood glucose levels and reduce the risk of complications. VILDIABATE PIO combines two potent diabetes medications: Vildagliptin (50 mg) and Pioglitazone Hydrochloride (15 mg). This combination leverages the complementary mechanisms of both drugs to offer an enhanced therapeutic effect. This article discusses the benefits, mode of action, and clinical utility of VILDIABATE PIO in the management of Type 2 diabetes.\n\nUnderstanding the Components of VILDIABATE PIO\nVildagliptin (50 mg)\nVildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances the body's natural ability to regulate blood sugar levels. It works by inhibiting the enzyme DPP-4, which is responsible for breaking down incretin hormones such as GLP-1 and GIP. These hormones play a crucial role in the regulation of glucose metabolism by increasing insulin release and decreasing glucagon secretion in response to meals, thereby aiding in the reduction of postprandial blood glucose levels.\n\nPioglitazone Hydrochloride (15 mg)\nPioglitazone is a type of medication known as a thiazolidinedione, which works primarily by increasing insulin sensitivity in peripheral tissues, such as muscle and fat. It also mildly suppresses hepatic gluconeogenesis. The overall effect is a reduction in insulin resistance, which is a core problem in Type 2 diabetes, making pioglitazone particularly effective for improving glucose control in patients who are insulin resistant.\n\nSynergistic Benefits for Diabetes Management\nEnhanced Glycemic Control\nBy combining Vildagliptin and Pioglitazone, VILDIABATE PIO addresses two major aspects of diabetes management: postprandial glucose spikes and insulin resistance. Vildagliptin improves the incretin system, enhancing pancreatic response to glucose intake, while Pioglitazone works to improve the effectiveness of endogenous insulin. This dual action is effective in reducing both fasting and postprandial blood glucose levels, offering comprehensive glycemic management.\n\nReduced Risk of Hypoglycemia\nVILDIABATE PIO provides a significant advantage in terms of safety. The mechanism of action of both Vildagliptin and Pioglitazone does not inherently cause hypoglycemia as they do not directly stimulate excessive insulin secretion. This makes the combination safer compared to other therapies that might induce hypoglycemia, especially beneficial for elderly patients or those with renal impairment.\n\nBenefits Beyond Glucose Control\nIn addition to controlling blood sugar, Pioglitazone has been shown to have favorable effects on lipid profiles, potentially lowering triglycerides and increasing HDL cholesterol. This cardiovascular risk reduction is an important aspect of diabetes care, given the high risk of heart disease associated with diabetes.\n For further information: \n EMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP:: 7877551268, 8209542042, 8955945010, 6377716668 \nhttps://www.sterisonline.com/product/vildiabate-pio-134257", "price": 295.0, "discountamount": 88.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 0, "_keywords": [ "fat", "body", "GIP.", "mode", "GLP-1", "EMAIL", "meals", "drugs", "terms", "enzyme", "safety", "muscle", "fasting", "article", "addition", "high risk", "Components", "regulation", "combination", "dual action", "information", "sterisonline", "Introduction", "Vildagliptin", "sterispharma", "crucial role", "Hypoglycemia", "core problem", "Reduced Risk", "heart disease", "CALL/WHATSAPP", "complications", "triglycerides", "effectiveness", "diabetes care", "lipid profiles", "glucose intake", "VILDIABATE PIO", "overall effect", "other therapies", "incretin system", "HDL cholesterol", "natural ability", "glucose control", "insulin release", "important aspect", "elderly patients", "clinical utility", "renal impairment", "DPP-4) inhibitor", "two major aspects", "thiazolidinedione", "incretin hormones", "favorable effects", "glucagon secretion", "peripheral tissues", "blood sugar levels", "glucose metabolism", "endogenous insulin", "insulin resistance", "pancreatic response", "insulin sensitivity", "Synergistic Benefits", "significant advantage", "dipeptidyl peptidase-4", "hepatic gluconeogenesis", "complementary mechanisms", "Enhanced Glycemic Control", "Pioglitazone Hydrochloride", "Type 2 diabetes management", "excessive insulin secretion", "enhanced therapeutic effect", "postprandial glucose spikes", "cardiovascular risk reduction", "two potent diabetes medications", "postprandial blood glucose levels", "comprehensive glycemic management", "multidimensional treatment strategy" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 948, "imageuri": "https://bizimages.withfloats.com/actual/a7e1548775604ef3baba96dfa8adc5cd.jpg", "tileimageuri": "https://bizimages.withfloats.com/actual/a7e1548775604ef3baba96dfa8adc5cd.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-04-27T10:56:25.768Z", "updatedon": "2024-04-27T10:56:25.768Z", "buyonlinelink": null, "producturl": "https://www.sterispharma.com/medicines/vildiabate-pio-/948", "availableunits": -1.0, "iscodavailable": true, "isprepaidonlineavailable": true, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Vildagliptin 50 mg & Pioglitazone Hydrochloride 15 mg", "category": "Diabetic Range", "tags": [ "Vicemic P", "Zomelis P", "Vildax P", "Vylda P", "Pioz-V", "Xilda P" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "AssuredPurchase", "producttype": "products", "hsncode": "", "gstslab": 0.0, "isnotforsale": false }, { "_id": "662cd7fae2fa911c8c291fac", "fptag": "STERISHEALTHCAREPVTLTDADA8", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VILDIABATE M 850 ", "description": "VILDIABATE M 850 \nMetformin (850mg)SR, Vildagliptin (50mg)\nIntroduction\nEffective management of Type 2 diabetes requires treatments that are not only effective in controlling blood glucose levels but also favorable in terms of side effects and patient adherence. VILDIABATE M 850, combining Metformin SR (850mg) with Vildagliptin (50mg), offers a potent and balanced approach to diabetes care. This article explores how this combination therapy works, its benefits, and the advantages it brings to patients dealing with Type 2 diabetes.\n\nUnderstanding the Components of VILDIABATE M 850\nMetformin SR (850mg)\nMetformin is a first-line medication in the management of Type 2 diabetes, known for its ability to reduce glucose production in the liver and improve insulin sensitivity in muscle and adipose tissues. The sustained-release (SR) formulation of 850mg allows for gradual release of the drug, which helps in maintaining steady blood glucose levels while minimizing gastrointestinal side effects commonly associated with higher doses of standard Metformin.\n\nVildagliptin (50mg)\nVildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the body’s natural ability to control high blood sugar by increasing the levels of incretin hormones. These hormones regulate glucose by increasing insulin release and decreasing glucagon secretion when needed, particularly after eating. This helps to control postprandial (post-meal) blood glucose spikes effectively.\n\nSynergistic Benefits for Diabetes Management\nComprehensive Glycemic Control\nVILDIABATE M 850 effectively targets both fasting and postprandial blood glucose levels. Metformin works primarily on reducing fasting glucose levels, while Vildagliptin manages post-meal spikes. This dual-action approach helps in achieving better overall glycemic control, which is crucial for reducing the risk of diabetes-related complications over time.\n\nReduced Risk of Hypoglycemia\nThe combination of Metformin and Vildagliptin is associated with a low risk of hypoglycemia. Unlike other diabetes treatments that may excessively stimulate insulin production, Vildagliptin enhances the body’s natural insulin response in a glucose-dependent manner, which prevents the unnecessary lowering of blood glucose levels.\n\nPositive Impact on Weight Management\nMetformin has been known to aid in weight loss or maintenance, which is an essential aspect of managing Type 2 diabetes. Vildagliptin is also weight-neutral, ensuring that VILDIABATE M 850 does not contribute to weight gain, making it an excellent option for patients concerned about their weight.\n\nIdeal Candidates for VILDIABATE M 850\nVILDIABATE M 850 is particularly suitable for individuals with Type 2 diabetes who:\n\nHave not achieved optimal glycemic control with other therapies.\nRequire a robust regimen to manage both fasting and postprandial glucose levels.\nAre looking for a diabetes treatment with minimal risks of hypoglycemia.\nNeed a medication that aligns with weight management goals.\nDosage and Administration\nVILDIABATE M 850 is typically prescribed as one tablet taken once or twice daily, depending on the individual's specific needs and glycemic targets. Taking this medication with meals can help optimize Metformin absorption and reduce potential gastrointestinal side effects.\n\nPotential Side Effects\nWhile VILDIABATE M 850 is generally well tolerated, some patients may experience side effects such as:\n\nGastrointestinal issues (less severe with the SR formulation).\nHeadache or common cold symptoms associated with Vildagliptin.\nRegular monitoring and communication with a healthcare provider are essential to manage any side effects and adjust the treatment as necessary.\nFor further information: \n EMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP:: 7877551268, 8209542042, 8955945010, 6377716668 \nhttps://www.sterisonline.com/product/vildiabate-m-850-133455\n\n", "price": 299.0, "discountamount": 89.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 0, "_keywords": [ "time", "drug", "body", "terms", "850mg", "meals", "liver", "EMAIL", "Dosage", "muscle", "option", "article", "Headache", "low risk", "patients", "one tablet", "Components", "advantages", "information", "individuals", "weight loss", "weight gain", "maintenance", "Vildagliptin", "higher doses", "Introduction", "VILDIABATE M", "sterisonline", "Reduced Risk", "Hypoglycemia", "sterispharma", "Metformin SR", "minimal risks", "CALL/WHATSAPP", "communication", "diabetes care", "specific needs", "robust regimen", "SR formulation", "Administration", "gradual release", "adipose tissues", "Type 2 diabetes", "other therapies", "Positive Impact", "natural ability", "insulin release", "essential aspect", "post-meal spikes", "high blood sugar", "DPP-4) inhibitor", "Ideal Candidates", "glycemic targets", "balanced approach", "patient adherence", "incretin hormones", "Regular monitoring", "insulin production", "glucose production", "glucagon secretion", "standard Metformin", "insulin sensitivity", "healthcare provider", "combination therapy", "Diabetes Management", "common cold symptoms", "unnecessary lowering", "Metformin absorption", "Synergistic Benefits", "dual-action approach", "Effective management", "first-line medication", "dipeptidyl peptidase-4", "fasting glucose levels", "Potential Side Effects", "Gastrointestinal issues", "weight management goals", "glucose-dependent manner", "overall glycemic control", "optimal glycemic control", "natural insulin response", "other diabetes treatments", "meal) blood glucose spikes", "postprandial glucose levels", "steady blood glucose levels", "Comprehensive Glycemic Control", "diabetes-related complications", "postprandial blood glucose levels", "sustained-release (SR) formulation", "potential gastrointestinal side effects" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 947, "imageuri": "https://bizimages.withfloats.com/actual/0f46d3a555df454c9cd942bbce090040.jpg", "tileimageuri": "https://bizimages.withfloats.com/actual/0f46d3a555df454c9cd942bbce090040.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-04-27T10:48:26.657Z", "updatedon": "2024-04-27T10:48:26.657Z", "buyonlinelink": null, "producturl": "https://www.sterispharma.com/medicines/vildiabate-m-850-/947", "availableunits": -1.0, "iscodavailable": true, "isprepaidonlineavailable": true, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Metformin (850mg)SR, Vildagliptin (50mg)", "category": "Diabetic Range", "tags": [ "Zomelis Met", "Vysov-M", "Vildagipt-MF", "Coniglip", "Vilglipt-M", "Valdiff-M", "Glipty M", "Vilcose M" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "AssuredPurchase", "producttype": "products", "hsncode": "", "gstslab": 0.0, "isnotforsale": false }, { "_id": "662cd51825c2821e38859500", "fptag": "STERISHEALTHCAREPVTLTDADA8", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VILDIABATE M 500 ", "description": "VILDIABATE M 500 \nMetformin (500mg)SR, Vildagliptin (50mg)\nIntroduction\nType 2 diabetes management can be complex, requiring a regimen that effectively controls blood glucose levels while minimizing side effects and enhancing patient adherence. VILDIABATE M 500, which combines Metformin SR (500mg) with Vildagliptin (50mg), provides a potent dual therapy that targets key aspects of diabetes control. This article explores the benefits, mechanisms of action, and clinical advantages of using VILDIABATE M 500 for managing Type 2 diabetes.\n\nUnderstanding the Components of VILDIABATE M 500\nMetformin SR (500mg)\nMetformin, a cornerstone in diabetes treatment, primarily works by reducing hepatic glucose production and improving insulin sensitivity in muscle and fat tissues. The sustained-release (SR) formulation allows for a gradual release of the medication, minimizing gastrointestinal side effects and providing a stable, prolonged effect, which is crucial for maintaining consistent blood glucose levels throughout the day.\n\nVildagliptin (50mg)\nVildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhancing the body's natural ability to control blood sugar levels post-meal. It works by inhibiting the enzyme that breaks down incretin hormones, thereby increasing their availability. Incretins help increase insulin release and decrease glucagon production in a glucose-dependent manner, effectively reducing postprandial glucose spikes.\n\nSynergistic Benefits for Diabetes Management\nComprehensive Glycemic Control\nVILDIABATE M 500 offers a comprehensive approach to managing blood glucose by targeting both fasting and postprandial levels. Metformin addresses fasting glucose by reducing liver glucose output and improving insulin sensitivity, while Vildagliptin controls postprandial spikes by enhancing the incretin effect.\n\nMinimized Risk of Hypoglycemia\nOne of the significant benefits of VILDIABATE M 500 is its low risk of causing hypoglycemia. Both Metformin and Vildagliptin do not typically induce hypoglycemia as they do not stimulate excessive insulin secretion. This makes VILDIABATE M 500 a safer option for patients, especially the elderly and those with renal impairment.\n\nWeight Management\nAnother advantage of VILDIABATE M 500 is its neutral impact on weight. Metformin has been known to aid in weight loss or maintain a neutral weight profile, and Vildagliptin does not contribute to weight gain. This aspect is particularly crucial in diabetes management, where weight control is often a key component of the overall treatment plan.\n\nIdeal Candidates for VILDIABATE M 500\nVILDIABATE M 500 is particularly suitable for individuals with Type 2 diabetes who:\n\nRequire an effective regimen to manage both fasting and postprandial blood glucose levels.\nAre concerned about the risks associated with hypoglycemia from other diabetes therapies.\nNeed a medication regimen that supports weight management.\nFor further information: \n EMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP:: 7877551268, 8209542042, 8955945010, 6377716668 \nhttps://www.sterisonline.com/product/vildiabate-m-500-133454", "price": 289.0, "discountamount": 86.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 0, "_keywords": [ "day", "body", "risks", "EMAIL", "500mg", "muscle", "action", "enzyme", "option", "fasting", "article", "patients", "low risk", "Incretins", "mechanisms", "Components", "weight loss", "weight gain", "fat tissues", "individuals", "information", "cornerstone", "key aspects", "Vildagliptin", "Metformin SR", "VILDIABATE M", "Introduction", "sterisonline", "availability", "sterispharma", "Hypoglycemia", "key component", "CALL/WHATSAPP", "neutral impact", "Minimized Risk", "weight control", "insulin release", "gradual release", "incretin effect", "natural ability", "Ideal Candidates", "DPP-4) inhibitor", "diabetes control", "renal impairment", "effective regimen", "patient adherence", "incretin hormones", "Weight Management", "medication regimen", "blood sugar levels", "diabetes treatment", "postprandial levels", "clinical advantages", "glucagon production", "postprandial spikes", "potent dual therapy", "insulin sensitivity", "liver glucose output", "Synergistic Benefits", "significant benefits", "neutral weight profile", "dipeptidyl peptidase-4", "overall treatment plan", "comprehensive approach", "glucose-dependent manner", "other diabetes therapies", "stable, prolonged effect", "hepatic glucose production", "Type 2 diabetes management", "postprandial glucose spikes", "excessive insulin secretion", "gastrointestinal side effects", "Comprehensive Glycemic Control", "consistent blood glucose levels", "postprandial blood glucose levels", "sustained-release (SR) formulation" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 946, "imageuri": "https://bizimages.withfloats.com/actual/51bf714506634c868ec05400177b9bd5.jpg", "tileimageuri": "https://bizimages.withfloats.com/actual/51bf714506634c868ec05400177b9bd5.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-04-27T10:36:08.705Z", "updatedon": "2024-06-22T12:39:03Z", "buyonlinelink": null, "producturl": "https://www.sterispharma.com/medicines/vildiabate-m-500-/946", "availableunits": -1.0, "iscodavailable": true, "isprepaidonlineavailable": true, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Metformin (500mg)SR, Vildagliptin (50mg)", "category": "Diabetic Range", "tags": [ "vildiabate m 500 uses in hindi", "vildapride m 50/500 alternative", "vildiabate m 1000", "vildapride m 50/1000", "vildapride m 500 tablet uses" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "AssuredPurchase", "producttype": "products", "hsncode": "", "gstslab": 12.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 10, "query": null, "floatingpoint": null }